Bruker 8-K
PositiveEarningsNew guidance
Scientific Instruments orders outpace sales; FY2026 outlook targets non-GAAP organic margin expansion on flat to low-single-digit organic revenue growth.
Filed 2026-01-12 12:00 ET
- 2.02 Results of Operations
- 7.01 Regulation FD Disclosure
Summary
Preliminary Q4 2025 results and FY2026 outlook. Bruker estimated Q4 revenue at $965M-$970M and reported that Bruker Scientific Instruments’ book-to-bill ratio was above 1.0. The FY2026 outlook calls for flat to low-single-digit organic revenue growth, higher non-GAAP organic operating margin and double-digit non-GAAP EPS growth, each compared with FY2025. Q4 estimates are preliminary and subject to change pending the close and audit.
Key Figures
| Metric | Q4 2025 | Q4 2024 | Y/Y |
|---|---|---|---|
| Revenue | $965M-$970M | — | — |
- Bruker Scientific Instruments segments’ book-to-bill ratio: above 1.0.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Organic revenue growth | FY2026 vs FY2025 | Flat to up low-single digits | — | — |
| Non-GAAP organic operating margin | FY2026 vs FY2025 | Expand 250-300 bp | — | — |
| Non-GAAP EPS growth | FY2026 vs FY2025 | Double digits | — | — |
Investor Takeaways
- Watch Bruker’s finalized Q4 and FY2025 results, which could differ materially from the preliminary revenue estimate.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3